CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April …
Category: Business
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling …
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the app…
20/20 Onsite Recognized by TITAN Health Awards for Transforming Healthcare Through Patient-Centric, Point-of-Need Ophthalmic Assessments
BOSTON–(BUSINESS WIRE)–20/20 Onsite has been named a Silver Winner in the 2025 TITAN Health Awards in Provider & Services – Healthcare.
Bruno Vision Care Receives FDA Approval for Deseyne® Contact Lens with FusionTechnology™
BOCA RATON, Fla.–(BUSINESS WIRE)–Bruno Vision Care LLC, a leader in eye care innovation, has received approval from the U.S. Food and Drug Administration (FDA) to sell its Deseyne® (vifilcon C) daily disposable contact lens with FusionTechnology™ in …
OneLegacy Celebrates Donate Life Month Through Outreach and Awareness Activities Promoting the Power of Organ, Eye and Tissue Donation
LOS ANGELES–(BUSINESS WIRE)–OneLegacy, the local organ procurement organization that serves seven counties in Southern California, is joining thousands of organizations, hospitals, transplant centers, and cities across the country to celebrate Nation…
NexThera Completes First Patient Enrollment in U.S. Clinical Trial for ‘NT-101,’ an Eye Drop Treatment for Wet AMD
BUSAN, South Korea–(BUSINESS WIRE)– #BiopharmaceuticalCompany–NexThera completed the initial patient enrollment for its Phase 1/2a clinical trial of NT-101, a novel eye drop treatment for wet AMD.
7 Major Markets Stargardt Disease (STGD) Epidemiology Forecasts Report 2020-2024 & 2034: Focus on United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Stargardt Disease (STGD) – Epidemiology Forecast – 2034” report has been added to ResearchAndMarkets.com’s offering. The report delivers an in-depth understanding of STGD, historical and forecasted epidemiology in the Unit…
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer…
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt…
Nexus Pharmaceuticals Launches Fluorescein 2 mL
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL vial alongside Fluorescein Injection, USP 10% in a 5 mL vial. Nexus is committed to enhanc…
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April
LONDON & SEATTLE–(BUSINESS WIRE)– #ophthalmology–Tenpoint Therapeutics Ltd. to Participate in the RBC Capital Markets Virtual Ophthalmology and 24th Annual Needham Virtual Healthcare Conferences
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. The Company also posted its fourth quarter Letter to…
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista pla…
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA–(BUSINESS WIRE)–Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA–(BUSINESS WIRE)–Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bau…
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
GENEVA–(BUSINESS WIRE)–Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
Alcon Agrees to Acquire LENSAR, Inc.
GENEVA, Switzerland & ORLANDO, Fla.–(BUSINESS WIRE)–Alcon Agrees to Acquire LENSAR, Inc.